DIRK REYN

University graduated Pharmacist (University of Antwerp) and MBA'er (Handelshogeschool, Kellogs, Chicago) with Marketing, Sales, Project Team, Crisis Management, Business Development, Investment, CEO and General Management skills acquired in the international pharmaceutical industry over a period of 35 years. Founder and CEO of MOVETIS (2006), biopharmaceutical Spin-off company from Janssen Pharmaceutica that went public and was sold to Shire. Founder and Chairman of Progress Pharma (2013). Currently co-founder and CEO of eTheRNA immunotherapies.

ABOUT DIRK

Dirk is married to Kristin and has two children, Michael and Birgit. His hobbies are music (High End Hi-Fi projects), Oldtimer cars (historical rally’s) and swimming/tennis.


INTERESTS

Founder of two basketball clubs and member of the Belgian National University and Military Basketball Team.
President of Regional chapter of Jaycees International between 1998 and 2002 and honorary member.
President Elect of Rotary Turnhout 2017-2018.
http://www.rotaryturnhout.be/
President of Moved to Help edition 2017, an annual charity event.
www.movedtohelp.be - In the news - On TV

Co-organiser of different musical events/concerts.
www.orgelvosselaar.be
Business sparring partner for Belgian artists in a changing music business model.


CAREER HISTORY

10's

Co-founder and currently CEO of eTheRNA immunotherapies, a spin- off company from the VUB Belgium. Closed a 24 MM series A financing with a syndicate of international investors in 2016.
eTheRNA immunotherapies is a pioneer in the development of mRNA-based immunotherapies for cancer, focusing on therapies that prepare and activate the immune system by programming dendritic cells (DC) with synthetic mRNA. eTheRNA uses its proprietary TriMix platform comprising three mRNA molecules that jointly have a boost effect on the activation and maturation of DCs, leading to potent population of both helper and cytotoxic T-cells.

Encouraged by impressive complete responses of combination therapy with TriMix-DC and ipilimumab in patients with advanced melanoma eTheRNA is committed to establish its TriMix technology as the gold standard in the wider area of onco-immunotherapy - both as a monotherapy in adjuvant settings and in combination with checkpoint inhibitors or other targeted therapies.

eTheRNA has made significant preclinical progress in developing TriMix not merely as an ex vivo product, but also as an in vivo formulation that can be made available ‘off the shelve’. eTheRNA is initiating phase I/II clinical studies with an in vivo injectable TriMix product in melanoma and triple negative breast cancer.
Dirk Reyn is a Venture Coach of bioqube ventures. In 2016, bioqube ventures partnered with Janssen Pharmaceutica NV (Janssen), part of the Janssen Pharmaceutical Companies of Johnson & Johnson to act as the independent management team leading the new Johnson & Johnson Innovation, JLINX initiative.
www.bioqubeventures.com
Currently Vice Chairman of Flanders Bio since 2013.
flandersbio.be
FlandersBio is the umbrella organization of Flemish biotech companies, research organisations and capital and service providers. FlandersBio is acting as a driving force for the sustained growth of the Flemish biotech industry by stimulating the flow of knowledge, creating a supportive environment, actively promoting entrepreneurship and improving the international visibility of Flanders as biotech region.
Ex-CEO, now chairman, and founder of Progress Pharma, an asset development company in 2013. Supported deal between Nestle and Lipid Therapeutics around a phase III asset in UC in 2015.
www.progresspharma.eu
Ex- Board member of Tigenix (public company in stem cells) and Zembro (digital alarm for elderly).
Completed the acquisition of Movetis by Shire in Aug 2010 and became Managing Director of the expanding Shire-Movetis site in Turnhout and Global General Manager for Resolor within the Shire group. Then became VP New Business Opportunities for Shire ex-US until end of 2012.

00's

Responsible for set up of two affiliates; Movetis GmbH in Germany and Movetis Ltd in the UK.
Obtained approval of RESOLOR, a novel medication for severe forms of constipation, in Europe in 2009 with Movetis team.
CEO, Founder and key champion of the creation of MOVETIS NV in 2006. Movetis NV was an independent Belgian biopharmaceutical company which specialized in developing new products for gastrointestinal (GI) disorders. Build company from scratch and secured more than 200 MM in a series ’A’ and IPO financing from major European and US investors.
Endorsed with the task to create an e-business excellence center and co-ordinate the required structures, processes and e-business offerings in the JNJ EMEA region leading up to full regional implementation of a common Internet and Siebel platform within Janssen Pharma.
As of 2001, responsible for New Business development in Europe for JNJ and one of team players in the closing of different deals including Velcade (Millenium), repurchasing of rights to Risperdal and Natrecor in Europe (Glaxo). Responsible of a team of 25 professionals all over Europe responsible for the commercial evaluation of all L&A opportunities within JNJ EMEA
Team leader of a team of 18 multidisciplinary teammembers from US and Beerse to manage the long-term strategy and regulatory negotiations of PREPULSID.

90's

As Senior Director GI between 1995 and 1997, key member of number of Project Team that facilitated in-licensing and launch of PARIET (rabeprazole, a reflux medication) from Eisai in 1994.
Member, between 1992 and 1995, of the International Strategic Marketing team that launched PREPULSID, a motility agent to treat reflux and dyspepsia, for Janssen-Cilag, a division of JNJ.

80's

Member of the Eli Lilly team between 1988 and 1992 that launched Prozac, an antidepressant, in Belgium and the US.


INTERESTING READS